Literature DB >> 15031290

Zn2+ inhibits glycine transport by glycine transporter subtype 1b.

Pengchu Ju1, Karin R Aubrey, Robert J Vandenberg.   

Abstract

In the central nervous system, glycine is a co-agonist with glutamate at the N-methyl-D-aspartate subtype of glutamate receptors and also an agonist at inhibitory, strychnine-sensitive glycine receptors. The GLYT1 subtypes of glycine transporters (GLYTs) are responsible for regulation of glycine at excitatory synapses, whereas a combination of GLYT1 and GLYT2 subtypes of glycine transporters are used at inhibitory glycinergic synapses. Zn2+ is stored in synaptic vesicles with glutamate in a number of regions of the brain and is believed to play a role in modulation of excitatory neurotransmission. In this study we have investigated the actions of Zn2+ on the glycine transporters, GLYT1b and GLYT2a, expressed in Xenopus laevis oocytes and we demonstrate that Zn2+ is a noncompetitive inhibitor of GLYT1 but has no effect on GLYT2. We have also investigated the molecular basis for these differences and the relationship between the Zn2+ and proton binding sites on GLYT1. Using site-directed mutagenesis, we identified 2 histidine residues, His-243 in the large second extracellular loop (ECL2) and His-410 in the fourth extracellular loop (ECL4), as two coordinates in the Zn2+ binding site of GLYT1b. In addition, our study suggests that the molecular determinants of proton regulation of GLYT1b are localized to the 2 histidine residues (His-410 and His-421) of ECL4. The ability of Zn2+ and protons to regulate the rate of glycine transport by interacting with residues situated in ECL4 of GLYT1b suggests that this region may influence the substrate translocation mechanism.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15031290     DOI: 10.1074/jbc.M312484200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  14 in total

Review 1.  N-acyl amino acids and N-acyl neurotransmitter conjugates: neuromodulators and probes for new drug targets.

Authors:  Mark Connor; Chris W Vaughan; Robert J Vandenberg
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

2.  Zinc inhibition of gamma-aminobutyric acid transporter 4 (GAT4) reveals a link between excitatory and inhibitory neurotransmission.

Authors:  Einav Cohen-Kfir; William Lee; Sepehr Eskandari; Nathan Nelson
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-13       Impact factor: 11.205

3.  The Concise Guide to PHARMACOLOGY 2013/14: transporters.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

4.  Dynamics of forward and reverse transport by the glial glycine transporter, glyt1b.

Authors:  Karin R Aubrey; Robert J Vandenberg; John D Clements
Journal:  Biophys J       Date:  2005-06-10       Impact factor: 4.033

5.  Oleoyl-L-carnitine inhibits glycine transport by GlyT2.

Authors:  J E Carland; R E Mansfield; R M Ryan; R J Vandenberg
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

6.  A novel dominant hyperekplexia mutation Y705C alters trafficking and biochemical properties of the presynaptic glycine transporter GlyT2.

Authors:  Cecilio Giménez; Gonzalo Pérez-Siles; Jaime Martínez-Villarreal; Esther Arribas-González; Esperanza Jiménez; Enrique Núñez; Jaime de Juan-Sanz; Enrique Fernández-Sánchez; Noemí García-Tardón; Ignacio Ibáñez; Valeria Romanelli; Julián Nevado; Victoria M James; Maya Topf; Seo-Kyung Chung; Rhys H Thomas; Lourdes R Desviat; Carmen Aragón; Francisco Zafra; Mark I Rees; Pablo Lapunzina; Robert J Harvey; Beatriz López-Corcuera
Journal:  J Biol Chem       Date:  2012-06-29       Impact factor: 5.157

7.  Modulation of glutamate and glycine transporters by niflumic, flufenamic and mefenamic acids.

Authors:  Suzanne Habjan; Robert J Vandenberg
Journal:  Neurochem Res       Date:  2009-05-15       Impact factor: 3.996

8.  Reversible inhibition of the glycine transporter GlyT2 circumvents acute toxicity while preserving efficacy in the treatment of pain.

Authors:  A Mingorance-Le Meur; P Ghisdal; B Mullier; P De Ron; P Downey; C Van Der Perren; V Declercq; S Cornelis; M Famelart; J Van Asperen; E Jnoff; J P Courade
Journal:  Br J Pharmacol       Date:  2013-11       Impact factor: 8.739

9.  Extracellular loops 2 and 4 of GLYT2 are required for N-arachidonylglycine inhibition of glycine transport.

Authors:  Amelia R Edington; Audra A McKinzie; Aaron J Reynolds; Michael Kassiou; Renae M Ryan; Robert J Vandenberg
Journal:  J Biol Chem       Date:  2009-10-29       Impact factor: 5.157

10.  Mutations in the GlyT2 gene (SLC6A5) are a second major cause of startle disease.

Authors:  Eloisa Carta; Seo-Kyung Chung; Victoria M James; Angela Robinson; Jennifer L Gill; Nathalie Remy; Jean-François Vanbellinghen; Cheney J G Drew; Sophie Cagdas; Duncan Cameron; Frances M Cowan; Mireria Del Toro; Gail E Graham; Adnan Y Manzur; Amira Masri; Serge Rivera; Emmanuel Scalais; Rita Shiang; Kate Sinclair; Catriona A Stuart; Marina A J Tijssen; Grahame Wise; Sameer M Zuberi; Kirsten Harvey; Brian R Pearce; Maya Topf; Rhys H Thomas; Stéphane Supplisson; Mark I Rees; Robert J Harvey
Journal:  J Biol Chem       Date:  2012-06-14       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.